Latest news with #DavidBaker
National Post
14 hours ago
- Business
- National Post
Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer
Article content CAMBRIDGE, Mass. — Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the appointment of David J. Baker, PhD, as Chief Scientific Officer (CSO). Article content 'David's extensive experience in drug discovery, with a strong track record of high performance and scientific leadership across the cardio-metabolic therapeutic area, makes him an ideal leader to advance our portfolio,' said Geoff MacKay, President & CEO of Fable. 'We are excited to welcome David to our leadership team and for him to guide Fable's scientific strategy and innovative platform.' Article content Dr. Baker contributes deep expertise leading highly successful teams from across industry and academia. Prior to joining Fable, Dr. Baker was Head of Metabolism Bioscience for Cardiovascular, Renal and Metabolism (CVRM) at AstraZeneca plc. He was responsible for guiding the metabolism portfolio from target selection to Ph2b in diabetes, obesity, MASH and dyslipidemia. Article content Dr. Baker joins Fable at a pivotal time to oversee the company's scientific strategy from discovery through to IND and first-in-human studies. 'I'm thrilled to be joining such a groundbreaking company with extremely talented individuals and looking forward to bringing new therapies to patients,' said Dr. Baker. Article content About Fable Therapeutics, Inc. Article content Fable Therapeutics, Inc. (Fable) is a discovery-stage biotechnology company that aims to improve the lives of the millions of people living with metabolic diseases including obesity and related comorbidities. Founded by veteran biotech entrepreneurs and leading computational scientists and backed by top-tier venture capital firms, Fable is applying an industry-leading sequence- and structure-based machine learning platform to design and optimize next-generation protein-based therapeutics. Fable's pipeline of therapeutics addresses validated target biology that has not yet been fully exploited owing to technical and development hurdles that are addressed by Fable's ML-enabled protein design engine. Article content Backed by a 2024 $43.5M Series A investment co-led by Versant Ventures and DCVC, Fable is leading in the purposeful integration of biology and computation to solve complex medical challenges. Fable's aspiration is to write the next chapter of what protein-based therapeutics can do, both through its internal pipeline and research and development partnerships with pharmaceutical companies. Fable has locations in Cambridge, MA and Toronto, Canada. Article content Article content Article content
BBC News
14-05-2025
- General
- BBC News
Wiltshire's oldest woman celebrates turning 111
Wiltshire's oldest woman, Anne Baker, has turned Baker, a mother-of-five who lives in Salisbury, was born just before World War One. She is also the oldest person to have received an MBE, which she was awarded aged 106 for fundraising for the National Society for the Protection of Children (NSPCC). Her son David Baker told the BBC his mother was "switched on" and likes to guess crossword clues. "She has always looked on the bright side of life, that's her real secret," he said, adding she has the "most beautiful smile". She spoke to the BBC, aged 107, about her 60 years of work for the NSPCC."The children are our future so I thought it was the best thing to think about," she said. Ms Baker also said she loved Salisbury and that her family was "all important". Her son David explained one of the stories she recounted a lot is remembering the butler coming into the room at the end of World War One with tears streaming down his face and asking if a flag could be said she was "not without tragedy", as her father died when she was 18 and her brother passed away in World War Two. As well as her extensive work for charity, Ms Baker is also an author. She started writing in her 50s, publishing four books."Occasionally we challenge her with a crossword and she gets quite a few clues. She's quite switched on," he said. "At that age, it's very difficult to converse. It's remembering exactly what you want to say in time". A bigger party is planned for Sunday at a local pub."She is so positive and we all love her," he added.
Associated Press
28-04-2025
- Business
- Associated Press
Quantumzyme Highlights Benefits and Commercialization Opportunities of Pending Breakthrough Green Chemistry Patent
SAN DIEGO, CA - April 28, 2025 ( NEWMEDIAWIRE ) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the key benefits and commercialization avenues of its soon to be published patented enzymatic process for sustainable ibuprofen production. This innovation not only strengthens Quantumzyme's leadership in green chemistry but also positions the company to capitalize on the global shift toward cleaner, more efficient manufacturing technologies. The process utilizes a specially engineered enzyme to streamline ibuprofen production, significantly reducing the use of harsh chemicals, solvents, and energy. By replacing traditional multi-step chemical synthesis with a selective biocatalytic transformation, Quantumzyme's method offers both environmental and economic advantages. Key Benefits of the Breakthrough Process: Quantumzyme plans to offer this soon to be patented process across multiple channels: 'Our enzymatic ibuprofen process exemplifies how cutting-edge science can address real-world industrial challenges,' stated Naveen Kulkarni, CEO of Quantumzyme. 'Through strategic commercialization, we aim to help manufacturers achieve regulatory compliance, meet ESG goals, and reduce costs - all while making chemistry greener.' This breakthrough directly resonates with the scientific momentum sparked by the 2024 Nobel Prize in Chemistry, awarded for advancements in computational enzyme design and protein structure prediction. Like Nobel laureates David Baker, Demis Hassabis, and John Jumper, Quantumzyme leverages artificial intelligence and protein engineering to revolutionize industrial chemistry - delivering sustainable, scalable solutions for the pharmaceutical sector. By combining green chemistry, computational design, and strategic commercialization, Quantumzyme's goal is to set new standards for the future of sustainable pharmaceutical production. For the most current information and updates, please visit our website at About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni Chief Executive Officer Quantumzyme Corp. 15656 Bernardo Center Drive, Suite 801 San Diego, CA 92127 Phone: +1 (858) 203-0312 Email: [email protected] Website: View the original release on
Observer
13-04-2025
- Business
- Observer
Bulgaria receives first US F-16
Bulgaria on Sunday welcomed its first US-made F-16 fighter jet ordered as part of the eastern-flank Nato member's landmark efforts to modernise its air force. To replace its Soviet-era MiG-29 jets, Bulgaria has ordered 16 American F-16s for a cost of around 2.4 billion euros ($2.7 billion), in the largest contract to overhaul its armed forces since the fall of communism in 1989. At a ceremony marking the jet's delivery at the Graf Ignatievo military base in central Bulgaria, Prime Minister Rossen Jeliazkov said those in attendance were celebrating "the inexorable and irreversible modernisation of the Bulgarian army. US defence official David Baker hailed the jet's delivery as a "significant milestone". "Your investments today will improve Bulgaria's security for decades to come and enable you to further contribute to making Nato the greatest military alliance in history," Baker added. After the first delivery on Sunday, seven more F-16s are due to be delivered by the end of 2025, with the remaining eight to arrive by 2027. Bulgaria, which last year celebrated the 20th anniversary of its entry into Nato, has for a long time delayed the modernisation of its air force for political and financial reasons. But as with other eastern members of the US-led defence alliance Russia's attack of Ukraine has forced a rethink of its defence posture. The poorest member of the European Union now spends more than the Nato-baseline two per cent of national output on defence -- though still well below the five per cent now demanded by US President Donald Trump. As a result of its ageing fleet, the country's fighter pilots lack training, according to a 2024 government report, which also pointed to a dearth of qualified personnel. In June 2021, a Bulgarian pilot died after his MiG-29 crashed during a military drill in the Black Sea. In September 2024, two more soldiers were killed during a training flight for an air show. rb/sbk/gv
